SRX sierra rutile holdings limited
Add to My Watchlist 0.00% ! 17.5¢

Phase 2 trial results presented at ASCO showed responses to...

  1. wild-1
    1,255 Posts.
    lightbulb Created with Sketch. 12
    clock Created with Sketch.
    03/06/15
    20:36
    Post #: 15407485
    Phase 2 trial results presented at ASCO showed responses to anti–PD-1 antibody pembrolizumab (Keytruda) in about 60% of colorectal cancers with MMR deficiency, but no responses in CRC lacking this feature. Link is below for those interested. Exciting result for that small subset of patients, which is only 4% of metastatic CRC. SIRT unlikely to be replaced by this expensive new therapy, I don't see why they couldn't be used together in the MMR deficient group.

    http://www.ascopost.com/ViewNews.aspx?nid=27670
    SRX Price at posting: $29.42 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Exploration drilling confirms large gold system at Abercromby Gold Project
right-arrow Created with Sketch.
CC9 Chariot to Acquire Majority Stake in a Nigerian Lithium Portfolio
right-arrow Created with Sketch.
NUZ Positive FDA feedback on NUZ-001 strategy to lift clinical hold
right-arrow Created with Sketch.
NEWS Trump just dropped a 200% tariff bomb. Here's how to cash in
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 017 – RBA holds the toppings
right-arrow Created with Sketch.
NEWS Rincon Lithium Project to be powered by 40MW energy infrastructure
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.